Lung Cancer: Types, Risk Factors, and Screening

Lung cancer is the leading cause of cancer death in the United States, accounting for more deaths annually than colorectal, breast, and prostate cancers combined (American Cancer Society, Cancer Facts & Figures 2023). This page covers the principal histological types, established risk factors, and evidence-based screening protocols that define current clinical and regulatory practice. Understanding the classification boundaries between lung cancer types matters because treatment selection, staging workup, and prognosis differ substantially across them. The pulmonaryauthority.com resource framework places lung cancer within the broader landscape of pulmonary conditions that require specialist evaluation.

Definition and scope

Lung cancer is a malignancy originating in the epithelial cells lining the airways or alveoli of the lung. It is broadly divided into two major histological categories recognized by the World Health Organization (WHO) Classification of Tumours of the Lung, Pleura, Thymus and Heart (5th edition): non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

NSCLC accounts for approximately 85% of all lung cancer diagnoses (National Cancer Institute SEER Program). It is further subdivided into three primary subtypes:

  1. Adenocarcinoma — the most common subtype in the United States, arising predominantly in peripheral lung tissue. It is the subtype most frequently diagnosed in never-smokers and in women.
  2. Squamous cell carcinoma — arises from bronchial epithelium, typically in central airways near the carina or main bronchi, and is strongly associated with tobacco exposure.
  3. Large cell carcinoma — a diagnosis of exclusion, representing roughly 10% of NSCLC cases, lacking the defining features of adenocarcinoma or squamous cell carcinoma on light microscopy.

SCLC comprises approximately 13–15% of lung cancers (NCI SEER). It is characterized by rapid doubling time, early hematogenous dissemination, and neuroendocrine differentiation. SCLC is staged under a two-category system — limited stage and extensive stage — rather than the TNM system used for NSCLC, reflecting its distinct biology and treatment pathway.

Rare subtypes include carcinoid tumors (typical and atypical), large cell neuroendocrine carcinoma, and pleural mesothelioma, the last of which, while not a primary lung parenchymal tumor, falls within the scope of thoracic oncology and pulmonary evaluation covered under the regulatory context for pulmonary medicine.

How it works

Lung carcinogenesis proceeds through accumulation of somatic mutations in airway epithelial cells, leading to uncontrolled proliferation. Tobacco smoke delivers more than 70 confirmed carcinogens (including polycyclic aromatic hydrocarbons and nitrosamines) that cause direct DNA adduct formation and strand breaks. The International Agency for Research on Cancer (IARC) classifies cigarette smoke as a Group 1 carcinogen — the highest evidence tier (IARC Monographs, Vol. 83).

In NSCLC adenocarcinoma, specific oncogenic driver mutations have been catalogued systematically. The most clinically actionable include:

Molecular profiling is now a standard element of workup per National Comprehensive Cancer Network (NCCN) Guidelines for Non-Small Cell Lung Cancer, which specify biomarker testing requirements for all newly diagnosed advanced NSCLC cases.

SCLC does not typically harbor targetable driver mutations at high frequency. Its biology is dominated by near-universal loss of RB1 and TP53 tumor suppressor function, consistent with its aggressive phenotype and initial chemosensitivity followed by rapid resistance.

Staging in NSCLC follows the American Joint Committee on Cancer (AJCC) TNM system, 8th edition, with stages IA through IVB determined by tumor size, nodal involvement, and metastatic spread. Five-year survival rates range from approximately 68% for stage IA1 to under 10% for stage IVB (AJCC Cancer Staging Manual, 8th ed.).

Common scenarios

Four clinical presentations recur with regularity in pulmonary practice:

1. Incidental nodule on imaging
A solitary pulmonary nodule discovered on chest CT or X-ray in an asymptomatic patient prompts risk stratification using validated tools such as the Fleischner Society Guidelines (2017) or the Lung-RADS classification system developed by the American College of Radiology (ACR). Nodule size, morphology, growth rate, and patient risk profile determine surveillance intervals. Guidance on chest CT findings and chest X-ray interpretation provides additional context for these evaluations.

2. Symptomatic presentation
Hemoptysis, persistent cough, unintentional weight loss, or new hoarseness prompts expedited workup. Central tumors — particularly squamous cell carcinoma and SCLC — more often present with endobronchial obstruction, post-obstructive pneumonia, or superior vena cava syndrome. Peripheral tumors may remain asymptomatic until locally advanced or metastatic.

3. Paraneoplastic syndromes
SCLC is the lung cancer subtype most associated with paraneoplastic phenomena, including syndrome of inappropriate antidiuretic hormone (SIADH), Lambert-Eaton myasthenic syndrome, and paraneoplastic encephalomyelitis, mediated by anti-neuronal antibodies.

4. Incidentally detected metastatic disease
Lung cancer frequently presents as brain metastases, adrenal masses, or bone lesions before a primary lung lesion is identified. PET-CT and brain MRI are standard components of staging workup per NCCN guidelines.

Lung cancer screening programs are explicitly designed to intercept disease at stage I or II, before symptomatic presentation dominates.

Decision boundaries

Clinical decisions in lung cancer hinge on four distinct classification axes:

NSCLC vs. SCLC
This is the primary fork. SCLC is treated with platinum-based chemotherapy (cisplatin or carboplatin plus etoposide) and immunotherapy in the extensive-stage setting, following FDA approval of atezolizumab in combination (IMpower133 trial data). NSCLC treatment is stratified further by stage, driver mutation status, and PD-L1 expression. Conflating SCLC with NSCLC at diagnosis has direct adverse consequences for treatment selection.

Resectable vs. unresectable NSCLC
Stages I, II, and selected IIIA tumors are evaluated for surgical resection, typically lobectomy, with curative intent. Unresectable stage III disease is treated with concurrent chemoradiation followed by durvalumab consolidation per FDA approval (PACIFIC trial). Stage IV disease is systemic therapy — targeted agents, immunotherapy, or chemotherapy depending on biomarker profile.

Driver-positive vs. driver-negative advanced NSCLC
Patients with EGFR mutations receive EGFR tyrosine kinase inhibitors (e.g., osimertinib, first-line per FLAURA trial data) rather than immunotherapy as initial treatment. ALK-rearranged tumors receive ALK inhibitors (alectinib, brigatinib, lorlatinib). In driver-negative tumors, PD-L1 expression ≥50% supports pembrolizumab monotherapy as first-line treatment per FDA labeling and KEYNOTE-024 trial data.

Screening eligibility
The U.S. Preventive Services Task Force (USPSTF) issued a 2021 recommendation (Grade B) for annual low-dose CT (LDCT) screening in adults aged 50–80 who have a 20-pack-year smoking history and currently smoke or quit within the past 15 years. The Centers for Medicare & Medicaid Services (CMS) aligned its coverage determination with this recommendation. Patients outside these parameters — including those with occupational radon or asbestos exposure without meeting smoking criteria — do not fall under the current USPSTF-defined screening threshold, though clinical judgment and individualized risk assessment may prompt further evaluation.

Tobacco cessation remains the highest-impact preventive intervention. The U.S. Public Health Service Clinical Practice Guideline on Treating Tobacco Use and Dependence identifies combination pharmacotherapy (varenicline plus counseling) as achieving quit rates approximately 3 times higher than unassisted cessation. Structural pathways for smoking cessation support are integrated into lung cancer risk reduction programs at major academic cancer centers.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)